User login
A supplement to Clinical Endocrinology News. This supplement was sponsored by DexCom, Inc.
• Interpreting the Data
• Time Needed to Interpret Data at Follow-Up Visits
• Training Patients to Initiate CGM
• Follow-Up Visits
• Summary
Faculty/Faculty Disclosure
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner and Diabetes Educator
Henry Ford Health System
Division of Endocrinology
Diabetes, Bone and Mineral Disorders
Detroit, MI
Ms Kruger is a consultant for Abbott Laboratories, Amylin Pharmaceuticals, Inc., Animas Corporation, a Johnson & Johnson Company, Calibra Medical, Inc., Eli Lilly and Company, and Novo Nordisk; serves on the speakers' bureau for Amylin, Lilly, Lilly-Amylin Alliance, and Novo Nordisk; and has received clinical research grant funding from Amylin, Calibra, DexCom, Inc., Eli Lilly and Company, Halozyme Therapeutics, Hoffman-La Roche Ltd, and the National Institutes of Health (NIH). She is also a stock shareholder of Amylin, DexCom, Hygieia Medical, and Patton Medical Devices and serves on the advisory board for Abbott, Animas, CADRE, CLINICAL ENDOCRINOLOGY NEWS, Eli Lilly, GlaxoSmithKline, Merck & Co., Inc., Novo Nordisk, Patton Medical Devices, and Tethys Bioscience, Inc.
Copyright © 2010 Elsevier Inc.
A supplement to Clinical Endocrinology News. This supplement was sponsored by DexCom, Inc.
• Interpreting the Data
• Time Needed to Interpret Data at Follow-Up Visits
• Training Patients to Initiate CGM
• Follow-Up Visits
• Summary
Faculty/Faculty Disclosure
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner and Diabetes Educator
Henry Ford Health System
Division of Endocrinology
Diabetes, Bone and Mineral Disorders
Detroit, MI
Ms Kruger is a consultant for Abbott Laboratories, Amylin Pharmaceuticals, Inc., Animas Corporation, a Johnson & Johnson Company, Calibra Medical, Inc., Eli Lilly and Company, and Novo Nordisk; serves on the speakers' bureau for Amylin, Lilly, Lilly-Amylin Alliance, and Novo Nordisk; and has received clinical research grant funding from Amylin, Calibra, DexCom, Inc., Eli Lilly and Company, Halozyme Therapeutics, Hoffman-La Roche Ltd, and the National Institutes of Health (NIH). She is also a stock shareholder of Amylin, DexCom, Hygieia Medical, and Patton Medical Devices and serves on the advisory board for Abbott, Animas, CADRE, CLINICAL ENDOCRINOLOGY NEWS, Eli Lilly, GlaxoSmithKline, Merck & Co., Inc., Novo Nordisk, Patton Medical Devices, and Tethys Bioscience, Inc.
Copyright © 2010 Elsevier Inc.
A supplement to Clinical Endocrinology News. This supplement was sponsored by DexCom, Inc.
• Interpreting the Data
• Time Needed to Interpret Data at Follow-Up Visits
• Training Patients to Initiate CGM
• Follow-Up Visits
• Summary
Faculty/Faculty Disclosure
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner and Diabetes Educator
Henry Ford Health System
Division of Endocrinology
Diabetes, Bone and Mineral Disorders
Detroit, MI
Ms Kruger is a consultant for Abbott Laboratories, Amylin Pharmaceuticals, Inc., Animas Corporation, a Johnson & Johnson Company, Calibra Medical, Inc., Eli Lilly and Company, and Novo Nordisk; serves on the speakers' bureau for Amylin, Lilly, Lilly-Amylin Alliance, and Novo Nordisk; and has received clinical research grant funding from Amylin, Calibra, DexCom, Inc., Eli Lilly and Company, Halozyme Therapeutics, Hoffman-La Roche Ltd, and the National Institutes of Health (NIH). She is also a stock shareholder of Amylin, DexCom, Hygieia Medical, and Patton Medical Devices and serves on the advisory board for Abbott, Animas, CADRE, CLINICAL ENDOCRINOLOGY NEWS, Eli Lilly, GlaxoSmithKline, Merck & Co., Inc., Novo Nordisk, Patton Medical Devices, and Tethys Bioscience, Inc.
Copyright © 2010 Elsevier Inc.
